| | Characteristic | High expression | Low expression | value |
| | Number of patients | 63 | 103 | | | Age, | | | 0.052 | | Weight, (median, IQR) | 63 (55, 69.5) | 65 (59.5, 72.5) | 0.117 | | BMI, (median, IQR) | 22.43 (19.58, 24.11) | 23.03 (20.79, 24.93) | 0.159 | | NLR, (median, IQR) | 1.9 (1.3, 2.73) | 1.95 (1.38, 2.6) | 0.987 | | PLR, (median, IQR) | 125.49 (100.25, 146.47) | 116.75 (95.03, 151.9) | 0.529 | | CD4, | | | 0.075 | | CD8, (median, IQR) | 23.3 (18.6, 29.85) | 21.6 (16.95, 26.75) | 0.170 | | CA19-9, (median, IQR) | 10.32 (6.21, 19.96) | 10.54 (6.21, 25.54) | 0.874 | | CA72-4, (median, IQR) | 3.65 (1.53, 6.55) | 2.19 (1.37, 6.03) | 0.105 | | CA125, (median, IQR) | 10.15 (6.95, 14.34) | 9.27 (6.52, 14.02) | 0.592 | | a Pathologic stage, (%) | | | < 0.001 | | I | 11 (6.6%) | 47 (28.3%) | | | II | 17 (10.2%) | 39 (23.5%) | | | III | 35 (21.1%) | 17 (10.2%) | | | Location, (%) | | | 0.003 | | L | 42 (25.3%) | 66 (39.8%) | | | M | 9 (5.4%) | 32 (19.3%) | | | U | 10 (6%) | 5 (3%) | | | Entire | 2 (1.2%) | 0 (0%) | | | WHO classification, (%) | | | 0.093 | | Mucinous | 8 (4.8%) | 5 (3%) | | | Poor differentiated | 10 (6%) | 27 (16.3%) | | | Signet ring cell | 19 (11.4%) | 22 (13.3%) | | | Well to moderate differentiated | 26 (15.7%) | 49 (29.5%) | | | Vascular invasion, (%) | | | 0.329 | | Negative | 50 (30.1%) | 89 (53.6%) | | | Positive | 13 (7.8%) | 14 (8.4%) | | | Neural invasion, (%) | | | 0.012 | | Negative | 27 (16.3%) | 66 (39.8%) | | | Positive | 36 (21.7%) | 37 (22.3%) | |
|
|
